FDA Grants Significant Approval to Vertex Pharmaceuticals

FDA Grants Significant Approval to Vertex Pharmaceuticals

Vertex Pharmaceuticals has recently achieved two significant FDA approvals in just 41 days. On December 20, 2024, the FDA approved Alyftrek for treating cystic fibrosis (CF), followed by the approval of Journavx, a novel treatment for moderate-to-severe acute pain, just a few days later.